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Supplement: Patients with RA usually experience substantial loss of lean mass (LM) (known as 'rheumatoid cachexia' (RC) (1) . This loss of LM is a major contributor to the decreased strength and impaired physical function (2,3) that characterizes RA.
Unfortunately, current pharmacologic treatments for RA do not ameliorate this LM loss, nor fully restore physical function (3) . Whilst exercise (specifically, progressive resistance training (PRT)) has been shown to be highly effective in restoring both LM and function in RA patients (2) , the lack of adherence to sufficiently intense training means this form of therapy is unlikely to be widely adopted (4) . Anabolic nutritional supplementation offers a potential adjunct treatment intervention for improving LM and function that should be widely acceptable. Indeed, our group (5) has previously demonstrated that daily oral protein supplementation for 12 weeks improved LM and some measures of objectively-assessed physical function in RA patients. Creatine (Cr), a combination of essential amino acids, is a popular dietary supplement generally shown to have greater benefits on both LM and physical function than generic protein.
To date, only one study (6) has investigated the efficacy of oral Cr supplementation in RA patients. In this uncontrolled trial, twelve patients underwent three weeks of supplementation, and although strength increased, body composition changes were not investigated.
To further investigate the efficacy of Cr supplementation in improving LM, strength and function in RA patients, we recruited 40 patients with stable RA disease (i.e. no change in medications in the preceding 3 months) from outpatient clinics. Participants were randomised to receive either supplementary Cr or placebo drinks for 12 weeks, with the groups matched for age and sex. Both the principle researcher (TW) and participants were blinded to supplement assignment.
In accordance with manufacture recommendations, and previous strategies (e.g. 6,7), the Cr group received 20 g of Cr monohydrate (4 x 5 g/day) for a 5-day 'loading phase' followed by 3 g/day for the remainder of the 12 week supplementation period ('maintenance dose'). The Cr was mixed with a mango-flavoured drink powder to improve taste. The placebo group received only the mango-flavoured drink powder. The appearance of the different treatment packets were indistinguishable, as were the flavouring and colouring of the drinks.
The flow of patients through the study is shown in Figure 1 . Subjects' baseline demographics are presented in Table 1 , and the effects of Cr supplementation on body composition in Table 2 . Twelve weeks of Cr supplementation resulted in a significant increase in ALM of 0.52 (±0.13) kg in the Cr group, with no change in the placebo group (0.05 (±0.13) kg; between-group P = .004, effect size (η 2 ) = .23 (medium)). Similarly, total LM increased by 0.60 (±0.37) kg) following Cr supplementation, with no change in the placebo group over the same period (-0.06 (±0.29) kg), albeit the between-group change was not significant (P = .158, η 2 = .06 (small)). In the Cr group there was an increase in intra-cellular water (ICW) from baseline to week 12 (0.64 ±0.22 L, P = .035, η 2 = .13 (medium)).
After 12 weeks of cessation of Cr supplementation (week 24), there was a regression towards baseline for ALM and total LM, which further supports a Cr treatment effect. No changes in FM or body fat % were observed at any time point for either group.
In contrast to the effects on muscle mass, Cr supplementation had no effect on objectively-assessed physical function ( Table 3 ).
The magnitude of LM increase we observed is comparable to that seen previously in older men and women following Cr supplementation. The body composition changes are also similar to those we previously observed following 12 weeks of protein supplementation in RA patients (i.e. increases of 0.40 kg in ALM and 0.73 kg in total LM, whilst FM remained unchanged (5)). These results, together with the response to PRT (2), and the finding that muscle quality (i.e. maximal force exerted per unit muscle)
is not impaired in RA patients (8) , further emphasise that RA patients are not, as once believed (9), resistant to muscle anabolic stimuli.
Interestingly, at week 24, despite the losses due to withdrawal of Cr, ALM and total LM were still 0.40 kg and 0.21 kg, respectively, above baseline values, suggesting some longer term retention of muscle mass following Cr supplementation.
The lack of a Cr-induced improvement in either strength or function that we observed in this study contrasts with the 14% gain in composite strength reported by Willer et al. (6) following short-term Cr supplementation in RA patients. However, the reported effects of Cr supplementation on measures of strength and function in older individuals are equivocal. Additionally, responsiveness to Cr supplementation is reported to vary, with only ~70-75% of individuals, irrespective of age, deemed to be 'responders' (7) . Consistent with this estimation, 80% of our participants 'responded', when 'response' is defined by increased ALM (≥0.24 kg).
Although the lack of effects on strength and physical function are disappointing, the increase in LM we demonstrated suggests that Cr supplementation may be beneficial in patients with severe RC, since a marked loss of LM both impairs the body's ability to fight infection due to limited expendable protein reserve for immune cell production, and increases the risk of mortality. The lack of efficacy demonstrated on physical function in this study further emphasises that sustained PRT (2) should be performed by RA patients wishing to substantially increase LM, and, subsequently, restore their strength and physical functioning.
The importance of this study: In patients with RA, 12 weeks of oral Cr supplementation had beneficial effects on muscle mass, but not on strength or objectively-assessed physical function. Given compliance to Cr was high, and no adverse treatment-related effects were observed, Cr may offer an acceptable, safe, low-cost, and reasonably effective means for RA patients with severe RC to help restore muscle mass. 
Figure 1. CONSORT diagram showing recruitment and path of patients through the study
GFR = (estimated) glomerular filtration rate; Cr = Creatine supplementation group; DNC = randomised but did not commence treatment (i.e. did not attend baseline and were subsequently withdrawn); * = due to missing data, final analysis for body composition data included values using Expectation-Maximization imputed data; # = missed sessions (placebo) at day 6, week 12 and week 24 were not the same participant.
